Sleeplessness · patients with chronic inflammatory demyelinating polyradiculoneuropathy
Monthly pulsed high‐dose dexamethasone may leads to lower sleeplessness compared with oral prednisolone (low certainty).
1 finding from 1 review
Moon facies · patients with chronic inflammatory demyelinating polyradiculoneuropathy
Monthly pulsed high‐dose dexamethasone probably leads to lower moon facies compared with oral prednisolone (moderate certainty).
1 finding from 1 review
Change in disability after one year · patients with chronic inflammatory demyelinating polyradiculoneuropathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Remission · patients with chronic inflammatory demyelinating polyradiculoneuropathy
Monthly pulsed high‐dose dexamethasone probably leads to higher remission at 12 months compared with oral prednisolone (moderate certainty).
1 finding from 1 review
≥ 1 point improvement on INCAT disability score at 12 months · patients with chronic inflammatory demyelinating polyradiculoneuropathy
Monthly pulsed high‐dose dexamethasone may leads to higher ≥ 1 point improvement on INCAT disability score at 12 months compared with oral prednisolone (low certainty).
1 finding from 1 review
Change in MRC sum score · patients with chronic inflammatory demyelinating polyradiculoneuropathy
1 finding from 1 review
Change in visual acuity (logMAR) ‐ 12 months (negative is better) · macular edema in diabetes
1 finding from 1 review
Cataract progression · macular edema in diabetes
Intravitreal dexamethasone implant 0.7 mg probably leads to higher cataract progression ‐ 12 to 24 months compared with intravitreal antiVEGF (moderate certainty).
1 finding from 1 review
RR 4.23 [2.36, 7.59]
Studies not reported
Moderate
Use of IOP‐lowering medications ‐ 24 months · macular edema in diabetes
Intravitreal dexamethasone implant 0.7 mg probably leads to higher use of IOP‐lowering medications ‐ 24 months compared with intravitreal antiVEGF (moderate certainty).
1 finding from 1 review
RR 4.76 [2.84, 7.99]
Studies not reported
Moderate
Surgery for glaucoma ‐ 24 months · macular edema in diabetes
It is very uncertain whether intravitreal dexamethasone implant 0.7 mg changes surgery for glaucoma ‐ 24 months compared with intravitreal antiVEGF (very low certainty).
1 finding from 1 review
RR 3.02 [0.12, 73.56]
Studies not reported
Very low
Gain 3+ lines of visual acuity at 1 year · macular edema in diabetes
Intravitreal dexamethasone implant 0.7 mg showed no clear difference in gain of three or more lines visual acuity ‐ 12 months compared with sham (moderate certainty).
1 finding from 1 review
Change in retinal thickness (micron) (negative is better) · macular edema in diabetes
1 finding from 1 review
Cataract progression · macular edema in diabetes
Intravitreal dexamethasone implant 0.7 mg probably leads to higher cataract progression ‐ 36 months compared with sham (moderate certainty).
1 finding from 1 review
Use of IOP‐lowering medications · macular edema in diabetes
Intravitreal dexamethasone implant 0.7 mg probably leads to higher use of IOP‐lowering medications ‐ 36 months compared with sham (moderate certainty).
1 finding from 1 review
Surgery for glaucoma · macular edema in diabetes
Intravitreal dexamethasone implant 0.7 mg showed no clear difference in surgery for glaucoma ‐ 36 months compared with sham (low certainty).
1 finding from 1 review
Change in visual acuity (logMAR) ‐ 12 months (negative is better) · macular edema in diabetes
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Gain 3+ lines of visual acuity at 1 year · macular edema in diabetes
Intravitreal dexamethasone implant 0.7 mg may leads to lower gain of three or more lines visual acuity ‐ 12 months compared with intravitreal antiVEGF (low certainty).
1 finding from 1 review
RR 0.99
Studies not reported
Low
Change in retinal thickness (micron) ‐ 12 months (negative is better) · macular edema in diabetes
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Mortality Mortality at latest · preterm infants with chronic lung disease
Systemic corticosteroids (dexamethasone or hydrocortisone) leads to lower mortality at latest reported age compared with control (placebo or nothing) (high certainty).
1 finding from 1 review
Bronchopulmonary dysplasia/chronic lung disease · preterm infants with chronic lung disease
Systemic corticosteroids (dexamethasone or hydrocortisone) probably leads to lower BPD at 36 weeks' PMA compared with control (placebo or nothing) (moderate certainty).
1 finding from 1 review